// App-Quantinova.ai

L02 : Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

Researchers

Presenter

  • Christopher Ritchlin

Principal Investigators

  • Laura Coates

  • Iain McInnes

  • Philip J. Mease

  • Joseph Merola

  • Yoshiya Tanaka

  • Akihiko Asahina

  • Laure Gossec

  • Alice Gottlieb

  • Diamant Thaci

  • Barbara Ink

  • Deepak Assudani

  • Rajan Bajracharya

  • Vish Shende

  • Jason Coarse

  • Robert Landewé

Medical Centers

  • University of Rochester Medcal Center, Rochester, NY

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France

  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

  • Comprehensive Center for Inflammation Medicine, University of Lubeck, Lubeck, Germany

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, NC

  • Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands

Locations

  • United States

  • United Kingdom

  • Japan

  • France

  • Germany

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT03895203

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved